Parkinson's disease is a common neurodegenerative syndrome characterized by loss of dopaminergic neurons in the substantia nigra, formation of filamentous intraneuronal inclusions (Lewy bodies), and an extra pyramidal movement disorder. Although several genes involved in familial Parkinson's disease have recently been identified, we still know very little about the molecular and biochemical events mediating neuronal dysfunction and death of dopaminergic neurons. To enable a comprehensive genetic analysis of Parkinson's disease, we have developed a Drosophila melanogaster model of the disorder. Expression of human a-synuclein in transgenic flies replicates the three cardinal manifestations of the human disease: adult-onset loss of dopaminergic neurons, filamentous intraneuronal inclusions containing a-synuclein, and progressive locomotor dysfunction. We now propose to exploit the genetic potential of the system by generating second site suppressors and enhancers of a-synuclein mediated neurodegeneration. A robust and titratable retinal phenotype suitable for genetic modification has been defined. Existing collections of well-defined mutant chromosomes will he assayed for their ability to modify the retinal phenotype. De novo mutations will also be generated and tested. Mutations that modify the retinal phenotype will be tested for their ability to alter dopaminergic neurodegeneration and inclusion formation. Modifiers of neurodegeneration and inclusion formation will be characterized molecularly. Mammalian homologues of these Drosophila modifiers will he human disease gene candidates and likely components of mammalian neurodegenerative pathways. We will also test the role of the ubiquitin/proteosome system, chaperones, and apoptosis in dopaminergic neurodegeneration using genetic methods. The role of the ubiquitin system and heat shock proteins will also be tested by looking for the presence of these proteins in Drosophila asynuclein aggregates. Ubiquitin co-localization studies will further address the relevance of the Drosophila system to human disease, because ubiquitination is a pervasive feature of human Lewy bodies. We can abolish inclusion formation in a-synuclein transgenic flies, and will determine if inclusions are required for neurotoxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS041536-02
Application #
6529708
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Murphy, Diane
Project Start
2001-09-01
Project End
2006-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
2
Fiscal Year
2002
Total Cost
$296,625
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Chen, Li; Periquet, Magali; Wang, Xu et al. (2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119:3257-65
Periquet, Magali; Fulga, Tudor; Myllykangas, Liisa et al. (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27:3338-46
Kontopoulos, Eirene; Parvin, Jeffrey D; Feany, Mel B (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15:3012-23
Chen, Li; Feany, Mel B (2005) Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8:657-63
Scherzer, Clemens R; Feany, Mel B (2004) Yeast genetics targets lipids in Parkinson's disease. Trends Genet 20:273-7
Greene, Jessica C; Whitworth, Alexander J; Kuo, Isabella et al. (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A 100:4078-83
Shulman, Joshua M; Feany, Mel B (2003) Genetic modifiers of tauopathy in Drosophila. Genetics 165:1233-42
Scherzer, Clemens R; Jensen, Roderick V; Gullans, Steven R et al. (2003) Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet 12:2457-66